Literature DB >> 10405928

HLA-DRB1 alleles and shared amino acid sequences in disease susceptibility and severity in patients from eastern France with rheumatoid arthritis.

E Toussirot1, B Auge, P Tiberghien, J Chabod, J P Cedoz, D Wendling.   

Abstract

OBJECTIVE: To examine the effects of HLA-DRB1 alleles and amino acid sequences that carry the shared epitope (SE) upon rheumatoid arthritis (RA) susceptibility and disease severity in patients from Eastern France.
METHODS: HLA-DRB1 alleles were determined in 120 patients and 104 healthy controls by polymerase chain reaction/sequence specific oligonucleotide probes. Subtyping of DRB1*01 and *04 were performed using sequence specific primers. Patients were retrospectively evaluated for disease duration, age at disease onset, presence of rheumatoid factors, subcutaneous nodules, vasculitis and other extraarticular diseases, for the need for arthroplasty and immunosuppressive/immunoregulatory agents, and for radiographic damage.
RESULTS: The prevalence of HLA-DRB1*04 was significantly higher in patients (46.6%) than in controls (17.3%) (Pcorr = 0.000003). HLA-DRB1*0101 and *0401 were the most prominently associated subtypes in patients with RA (33.3%, Pcorr = 0.011, and 28.3%, Pcorr = 0.00008, respectively). A significant fraction of patients (72.5%) expressed one or 2 copies of the SE (p < 0.0000001; OR 4.77, CI 2.61-8.78). The presence of double SE was associated with a higher risk of developing RA (OR 4.83, CI 1.91-12.71; p = 0.0001). No significant differences in the clinical records among patients expressing no RA linked alleles, one and 2 copies of the SE, were observed. However, analyzing the specific effect of each amino acid sequence, we observed a significant association of the QKRAA motif with vasculitis (p = 0.03) and history of joint replacement surgery (p = 0.05), suggesting a role for lysine in position 71 of the shared sequence.
CONCLUSION: These findings differ from those of previous HLA-DRB1 allele studies in patients with RA from other regions of France. Thus, the heterogeneity in both the expression of DRB1 alleles and the association of these alleles with disease severity could be relevant within a country such as France.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10405928

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

Review 2.  HLA and disease.

Authors:  Yogita Ghodke; Kalpana Joshi; Arvind Chopra; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

3.  The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population.

Authors:  H Marotte; B Pallot-Prades; L Grange; J Tebib; P Gaudin; C Alexandre; J L Blond; M A Cazalis; B Mougin; P Miossec
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

4.  Aspartic acid70 in the HLA-DRB1 chain and shared epitope alleles partially explain the high prevalence of autoimmunity in Mexicans.

Authors:  Luis Francisco Valdés-Corona; Susana Hernández-Doño; Tatiana Sofia Rodríguez-Reyna; Rafael García-Silva; Juan Jakez; Monica Escamilla-Tilch; Guadalupe Lima; Luis Llorente; Carlos Pineda; Edmond Yunis; Julio Granados
Journal:  J Transl Autoimmun       Date:  2020-05-15

Review 5.  Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

Authors:  Katherine A Lyseng-Williamson; Rachel H Foster
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  The association of HLA-DQB1, -DQA1 and -DPB1 alleles with anti- glomerular basement membrane (GBM) disease in Chinese patients.

Authors:  Huan Luo; Min Chen; Zhao Cui; Rui Yang; Peng-Cheng Xu; Xu-Jie Zhou; Ming-Hui Zhao
Journal:  BMC Nephrol       Date:  2011-05-13       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.